SpyGlass Pharma Presents 18-Month Data Demonstrating Improvements in Visual Acuity with IOL-Mounted Drug Delivery Platform
SpyGlass Pharma announced that 18-month data from the first-in-human study of the SpyGlass Drug Delivery Platform demonstrated improvements in both visual acuity and IOP outcomes, key objectives for long-term treatment of glaucoma or ocular hypertension. The data was highlighted in a poster presentation at the ASCRS annual meeting in Los Angeles.
The single-center, prospective, cohort study included 23 patients with a visually significant cataract and concomitant glaucoma or ocular hypertension. All patients received the SpyGlass IOL-based drug delivery platform at the time of cataract surgery. Results showed that BCDVA improved from 20/30-20/100 at baseline to 20/16-20/30 at 18 months. Mean IOP was significantly reduced from 25.1 ± 2.5 mmHg at baseline post-washout to 14.1 ± 2.6 mmHg at 18 months (P<0.0001). All patients remained off all topical IOP-lowering medications. There was no statistically significant difference in IOP reduction across the three dosage groups tested, and no product-related adverse events were observed in the study.
“In the US, 5 million cataract surgeries are performed annually, with 20% occurring in patients who also have increased IOP caused by open-angle glaucoma or ocular hypertension. Our compelling 18-month results highlight the potential long-term benefits of the SpyGlass Drug Delivery Platform for these patients,” said Malik Kahook, MD, Co-founder of SpyGlass Pharma. “The promising improvement in visual acuity, along with the clinically meaningful reduction in IOP, reinforce our confidence in the platform, and we look forward to sharing these data with the ophthalmic community at ASCRS.”
“We continue to see the SpyGlass Drug Delivery Platform poised to reimagine the treatment paradigm by addressing the unmet need of long-term drug delivery while also utilizing a familiar implantation technique for cataract surgeons,” said Patrick Mooney, CEO, SpyGlass Pharma. “This promising dataset bolsters the potential for long-term durability of both visual outcomes and IOP lowering efficacy. We look forward to providing further data updates from this ongoing study."